Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts hold a “Moderate Buy” consensus on Agios Pharmaceuticals, with five buy ratings, one strong buy, four holds and one sell. The average 12-month price target is $41.75, above the stock’s $33.95 opening price.
• Recent firms generally raised their targets, including HC Wainwright to $55 and Citigroup to $52, while TD Cowen upgraded the stock to “strong buy”; JPMorgan maintained a neutral rating with a $34 target.
• Agios reported quarterly revenue of $44.75 million, exceeding estimates, but its loss of $1.69 per share was slightly wider than expected. An insider also sold 30,000 shares, while several institutional investors increased their holdings.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $41.75.

Several research firms recently weighed in on AGIO. HC Wainwright raised their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. boosted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Weiss Ratings reissued a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Citigroup raised their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Finally, TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 24th.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider owned 54,645 shares of the company's stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Sei Investments Co. boosted its stake in shares of Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company's stock valued at $2,150,000 after purchasing an additional 49,198 shares in the last quarter. SCS Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $22,743,000. Seven Fleet Capital Management LP acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $864,000. GW&K Investment Management LLC increased its stake in shares of Agios Pharmaceuticals by 41.5% in the fourth quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company's stock valued at $32,863,000 after buying an additional 354,359 shares during the period. Finally, Erste Asset Management GmbH raised its holdings in Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company's stock valued at $76,343,000 after buying an additional 40,000 shares during the last quarter.

Agios Pharmaceuticals Trading Up 2.7%

Shares of AGIO opened at $33.95 on Tuesday. The company's fifty day simple moving average is $34.28 and its 200 day simple moving average is $32.20. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -4.84 and a beta of 0.60.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. As a group, research analysts forecast that Agios Pharmaceuticals will post -5.82 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company's research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.